MicroRNA Expression Profiling for Oocyte Competence Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for selecting embryos with high implantation potential in IVF are limited by morphological criteria, leading to low pregnancy rates and high failure rates in assisted reproductive technology, with over 50% of IVF-born babies resulting from multiple gestations, which incur significant healthcare costs.
Innovation Solution
A method involving the measurement of specific microRNA expression levels in cumulus cells surrounding oocytes or embryos, including hsa-mir-103-1, hsa-mir-1826, hsa-let-7a-1, and others, to predict oocyte and embryo competence, allowing for the selection of viable embryos with high implantation potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If morphological criteria are used for embryo selection, then the selection process is simple and non-invasive, but the predictive power is limited and pregnancy rates remain low
Solution Approach 1:
The patent uses cumulus cells as an intermediary to indirectly assess oocyte and embryo competence. Instead of directly analyzing the oocyte or embryo (which would be invasive), the method measures microRNA expression in the surrounding cumulus cells, which reflect the biological state of the oocyte-embryo complex. This intermediary approach enables reliable prediction without direct invasion of the reproductive cells.
Solution Approach 2:
The patent shifts from morphological parameters (visual characteristics) to molecular parameters (microRNA expression levels). By measuring the expression levels of specific microRNAs in cumulus cells, the method transitions from subjective morphological assessment to objective molecular profiling, significantly improving predictive accuracy for implantation potential and pregnancy outcome.
2Reliability
If direct biomarker analysis of oocytes or embryos is performed, then predictive accuracy improves, but invasive methods are required which raise legal and ethical concerns
Solution Approach 1:
The patent employs cumulus cells as a non-invasive intermediary that surrounds and communicates with the oocyte. By analyzing microRNA expression in these accessible cumulus cells rather than directly in the oocyte or embryo, the method achieves high predictive accuracy while avoiding invasive procedures that would harm or alter the reproductive cells.
Solution Approach 2:
The patent creates a molecular copy profile of the oocyte-embryo complex through microRNA expression analysis in cumulus cells. This copying approach captures the biological state and competence indicators without physically altering or invading the original oocyte or embryo, thus maintaining their integrity while achieving accurate prediction.
3Reliability
If multiple embryos are transferred to increase pregnancy rates, then pregnancy success improves, but multiple gestations increase leading to higher healthcare costs
Solution Approach 1:
The patent replaces mechanical embryo selection methods (transferring multiple embryos to ensure pregnancy) with a molecular diagnostic system. By using microRNA expression profiling to identify single competent embryos with high implantation potential, the method substitutes physical multiple transfers with precise molecular selection, reducing multiple gestations and associated healthcare costs while maintaining high pregnancy rates.
Solution Approach 2:
The patent changes the selection parameter from quantity (number of embryos transferred) to quality (molecular competence profile). By selecting embryos based on their microRNA expression profile indicating high competence rather than transferring multiple embryos to compensate for low individual success rates, the method optimizes pregnancy outcome while minimizing healthcare resource consumption.
Data Source
Figure 1~2
Figure 3~4
AI summary
The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.